Literature DB >> 33300633

Activation of nuclear factor-κB in the angiogenesis of glioma: Insights into the associated molecular mechanisms and targeted therapies.

Jiajie Tu1, Yilong Fang1, Dafei Han1, Xuewen Tan1, Haifeng Jiang1, Xun Gong1, Xinming Wang2, Wenming Hong2, Wei Wei1.   

Abstract

Glioma is the most commonly observed primary intracranial tumour and is associated with massive angiogenesis. Glioma neovascularization provides nutrients for the growth and metabolism of tumour tissues, promotes tumour cell division and proliferation, and provides conditions ideal for the infiltration and migration of tumour cells to distant places. Growing evidence suggests that there is a correlation between the activation of nuclear factor (NF)-κB and the angiogenesis of glioma. In this review article, we highlighted the functions of NF-κB in the angiogenesis of glioma, showing that NF-κB activation plays a pivotal role in the growth and progression of glioma angiogenesis and is a rational therapeutic target for antiangiogenic strategies aimed at glioma.
© 2020 The Authors. Cell Proliferation Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Glioma; NF-κB; angiogenesis

Mesh:

Substances:

Year:  2020        PMID: 33300633      PMCID: PMC7848966          DOI: 10.1111/cpr.12929

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  141 in total

Review 1.  Histopathological evaluation of apoptosis in cancer.

Authors:  Y Soini; P Pääkkö; V P Lehto
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

2.  Association of a single nucleotide polymorphism in the matrix metalloproteinase-1 promoter with glioblastoma.

Authors:  Jessica McCready; William C Broaddus; Virginia Sykes; Helen L Fillmore
Journal:  Int J Cancer       Date:  2005-12-10       Impact factor: 7.396

3.  Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest.

Authors:  Tadashi Yoshii; Tomoharu Fukumori; Yuichiro Honjo; Hidenori Inohara; Hyeong-Reh Choi Kim; Avraham Raz
Journal:  J Biol Chem       Date:  2001-11-27       Impact factor: 5.157

4.  Glycitein inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9 gene expression.

Authors:  Eun-Jung Lee; So-Young Kim; Jin-Won Hyun; Sung-Won Min; Dong-Hyun Kim; Hee-Sun Kim
Journal:  Chem Biol Interact       Date:  2010-02-25       Impact factor: 5.192

5.  Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma.

Authors:  Tong-Xin Xie; Zhibo Xia; Nu Zhang; Weida Gong; Suyun Huang
Journal:  Oncol Rep       Date:  2010-03       Impact factor: 3.906

Review 6.  Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature.

Authors:  Ajaya Kumar A; Abu Abraham Koshy
Journal:  World Neurosurg       Date:  2017-09-01       Impact factor: 2.104

7.  mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.

Authors:  Markus Weiler; Jonas Blaes; Stefan Pusch; Felix Sahm; Marcus Czabanka; Sebastian Luger; Lukas Bunse; Gergely Solecki; Viktoria Eichwald; Manfred Jugold; Sibylle Hodecker; Matthias Osswald; Christoph Meisner; Thomas Hielscher; Petra Rübmann; Philipp-Niklas Pfenning; Michael Ronellenfitsch; Tore Kempf; Martina Schnölzer; Amir Abdollahi; Florian Lang; Martin Bendszus; Andreas von Deimling; Frank Winkler; Michael Weller; Peter Vajkoczy; Michael Platten; Wolfgang Wick
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-23       Impact factor: 11.205

8.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

9.  Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy.

Authors:  Qian Huang; Fang Li; Xinjian Liu; Wenrong Li; Wei Shi; Fei-Fei Liu; Brian O'Sullivan; Zhimin He; Yuanlin Peng; Aik-Choon Tan; Ling Zhou; Jingping Shen; Gangwen Han; Xiao-Jing Wang; Jackie Thorburn; Andrew Thorburn; Antonio Jimeno; David Raben; Joel S Bedford; Chuan-Yuan Li
Journal:  Nat Med       Date:  2011-07-03       Impact factor: 53.440

10.  PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma.

Authors:  Tianrun Liu; Wenjuan Ma; Haineng Xu; Menggui Huang; Duo Zhang; Zhenqiang He; Lin Zhang; Steven Brem; Donald M O'Rourke; Yanqing Gong; Yonggao Mou; Zhenfeng Zhang; Yi Fan
Journal:  Nat Commun       Date:  2018-08-27       Impact factor: 14.919

View more
  4 in total

1.  Machine Learning-Based Analysis of Glioma Grades Reveals Co-Enrichment.

Authors:  Mateusz Garbulowski; Karolina Smolinska; Uğur Çabuk; Sara A Yones; Ludovica Celli; Esma Nur Yaz; Fredrik Barrenäs; Klev Diamanti; Claes Wadelius; Jan Komorowski
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

Review 2.  Activation of nuclear factor-κB in the angiogenesis of glioma: Insights into the associated molecular mechanisms and targeted therapies.

Authors:  Jiajie Tu; Yilong Fang; Dafei Han; Xuewen Tan; Haifeng Jiang; Xun Gong; Xinming Wang; Wenming Hong; Wei Wei
Journal:  Cell Prolif       Date:  2020-12-10       Impact factor: 6.831

Review 3.  The role of long non-coding RNAs in angiogenesis and anti-angiogenic therapy resistance in cancer.

Authors:  Junxia Liu; Qinqiu Zhang; Daolu Yang; Fei Xie; Zhaoxia Wang
Journal:  Mol Ther Nucleic Acids       Date:  2022-03-15       Impact factor: 10.183

4.  Targeting of the COX-2/PGE2 axis enhances the antitumor activity of T7 peptide in vitro and in vivo.

Authors:  Jianrong Yang; Jingtao Zhong; Mi Zhou; Yinghong Zhou; Peng Xiu; Feng Liu; Fuhai Wang; Zelun Li; Yuntian Tang; Yuanyuan Chen; Siyang Yao; Tao Huang; Tianqi Liu; Xiaofeng Dong
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.